OncoTriage. Поиск наилучшего лечения для вашего пациента

ХМПН

Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.

We make recommendations based on 15 years of experience in using ruxolitinib and other JAK inhibitors for the treatment of myelofibrosis. We discuss when allogeneic haematopoietic stem cell transplantation (AHSCT) should be considered and some of the currently available alternative JAK inhibitors and trial options when AHSCT is not an option.

DOI: 10.1002/jha2.70007

Butler LA, Forsyth C, Harrison C, Perkins AC

EJHaem, 2025-04-03

НОВАЯ СТАТЬЯ

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

The ROMEI study demonstrated the importance of optimal ruxolitinib dosage in patients with MF for maximum effectiveness and improved OS, with manageable safety.

DOI: 10.1002/cncr.35801

Breccia M, Palandri F, Martelli M, Mendicino F, Malato A, Palumbo GA, Sibilla S, Di Renzo N, Abruzzese E, Siragusa S, Crugnola M, Selleri C, Pane F, Sportoletti P, Martino B, Impera S, Ricco A, Langella M, Ditonno P, Carli G, Itri F, Liberati AM, Urb

Cancer, 2025-04-03

НОВАЯ СТАТЬЯ

Distribution of BCR::ABL1 Transcript Types and Response to Therapy in Pediatric Patients with Chronic Myeloid Leukemia.

Achieving a stable deep molecular response with the option to discontinue tyrosine kinase inhibitor treatment is the new therapeutic goal for patients with chronic myeloid leukemia (CML)...

DOI: 10.1016/j.jmoldx.2024.12.010

Seiser E, Behrens YL, Lukat S, Sembill S, Karow A, Suttorp M, Metzler M, Krumbholz M

The Journal of molecular diagnostics : JMD, 2025-04-03

НОВАЯ СТАТЬЯ

Tyrosine Kinase Inhibitor Treatment Patterns in Patients With Chronic-Phase Chronic Myeloid Leukemia: A Single Center Data From China.

These findings emphasized the complexities involved in the management of patients with CP-CML and highlighted the importance of personalized treatment strategies.

DOI: 10.1016/j.clml.2024.12.008

Yuan MY, Zhang XS, Jiang Q

Clinical lymphoma, myeloma & leukemia, 2025-04-03

НОВАЯ СТАТЬЯ

Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors.

У данной статьи нет абстракта.

DOI: 10.3324/haematol.2024.286867

Aperna F, Alsugair AK, Fathima S, Tefferi A, Gangat N

Haematologica, 2025-04-03

НОВАЯ СТАТЬЯ

Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase.

Ponatinib discontinuation is feasible in patients with CML-CP failing prior TKIs. Patients who achieve sustained MR4.5 for at least 2 years have the highest likelihood of remaining in treatment-free remission following ponatinib discontinuation.

DOI: 10.1016/j.clml.2024.11.003

Haddad FG, Sasaki K, Senapati J, Hu S, Dellasala S, Issa GC, Jabbour E, Kantarjian H

Clinical lymphoma, myeloma & leukemia, 2025-04-03

Impact of national volume-based procurement policy on drugs treating chronic Myelogenous Leukemia.

The National Volume-Based Procurement policy effectively reduced the unit price of relevant drugs and increased their utilization, thereby improving drug affordability and reducing the financial burden on CML patients requiring long-term treatment.

DOI: 10.1186/s41043-025-00829-y

Yang Z, Li Y, Liu S, Han X, Wu Y, Fan X, Li Y, Jiang B

Journal of health, population, and nutrition, 2025-04-02

Наверх

ХМПН

Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Distribution of BCR::ABL1 Transcript Types and Response to Therapy in Pediatric Patients with Chronic Myeloid Leukemia.

Tyrosine Kinase Inhibitor Treatment Patterns in Patients With Chronic-Phase Chronic Myeloid Leukemia: A Single Center Data From China.

Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors.

Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase.

Impact of national volume-based procurement policy on drugs treating chronic Myelogenous Leukemia.

Свяжитесь с нами

Вход в аккаунт

Восстановление пароля